BioDelivery Sciences International (BDSI) announced Monday morning that its Phase 3 clinical study of Clonidine Topical Gel did not meet its primary endpoint.
BioDelivery Sciences International gapped open sharply lower Monday, but was range-bound for the majority of the session. Shares finished with a loss of 3.38 at $10.51, on the highest volume in over 8 months. The stock sank to over a 9 1/2 month low.
For comments and feedback contact: editorial@rttnews.com
Business News